In conclusion, we demonstrated that serum levels of TGF-β isoforms were significantly lower in patients with subclinical atherosclerosis and predicted reduced risk for subclinical atherosclerosis in South African patients with CKD. Here, TGFB1 is linked to chronic kidney disease.